Summary
The U.S. Food and Drug Administration (FDA) has approved Mounjaro to reduce the risk of heart events, including heart attacks, in individuals with diabetes. Developed by Eli Lilly, Mounjaro targets GLP-1 and GIP hormones, and a study showed an 8% lower rate of heart attack, stroke, or heart-related death compared to another diabetes drug, Trulicity.